VBL Theraputics

Since 2000 / Life Sciences

www.vblrx.com

    CEO

    Prof. Dror Harats MD

    NEWS

    VBL Therapeutics Reports Topline Results From Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis

    Read More >

    VBL Therapeutics Announces Removal of FDA Partial Clinical Hold on VB-111

    Read More >

    Vascular Biogenics (VBL) Ltd. is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. VBL Therapeutics' clinical pipeline is based on two distinct, proprietary platform technologies—an oncology program and an anti-inflammatory program—that leverage the body's natural physiologic and genetic regulatory elements.

    VBL’s oncology program is based on the Company’s proprietary Vascular Targeting System™ or VTS platform technology which utilizes genetically targeted therapy to destroy newly formed blood vessels. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma. VB-111 has received orphan drug designation in both the US and Europe and was granted Fast Track designation by the FDA. VBL Therapeutics expects to begin the pivotal Phase 3 trial for VB-111 in rGBM in the first half of 2015, under an SPA granted by the FDA.

    VBL’s anti-inflammatory program is based on the Lecinoxoids platform technology. Lecinoxoids are a novel class of small molecules developed by VBL that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. VB-201, the lead product candidate from VBL’s anti-inflammatory program, is a proprietary, first-in-class, specific innate immunity disease-modifying medicine in development for the effective treatment of chronic immune-inflammatory diseases. VB-201 has completed Phase 2 clinical trials for psoriasis and ulcerative colitis, with top-line results expected in the first quarter of 2015.

    Both compounds target markets with unmet need for safe and well-tolerated treatments, and provide differentiation from current or proposed treatments. We believe our two distinct platform technologies provide us with an opportunity to develop a diversified portfolio of product candidates targeting both orphan indications and large markets.